

# Therapies for AL Amyloidosis: 2026

Traditional Antibodies	Alkylating Agents	Proteasome Inhibitors	Steroids	IMiDs and CELMoDs	Bispecific Abs and Cellular Therapies	Novel Therapies	Anti-Fibril Agents
Daratumumab (Darzalex)	Cyclophosphamide (Cytoxan)	Bortezomib (Velcade)	Dexamethasone (Decadron)	Thalidomide (Thalomid)	Teclistamab (Tecvayli)	Venetoclax (Venclexta)	Anselamimab (CAEL101)
Isatuximab (Sarclisa)	Melphalan (Alkeran)	Ixazomib (Ninlaro)	Prednisone	Lenalidomide (Revlimid)	Elranatamab (Elrexfio)		Zamubafusp-alfa (AT-02)
Elotuzumab (Empliciti)	High-Dose Melphalan	Carfilzomib (Kyprolis)		Pomalidomide (Pomalyst)	Linvoseltamab (REGN4548)		AT-03 (PAR-SAP)
Belantamab (Blenrep)	Bendamustine (Treanda)			Iberdomide (CC220)	Etentamig (ABBV-383)		
				Mezigdomide (CC-92480)	CART Cells* (BCMA-Directed)		
					AT-06 (PAR CAR-M)		
					Talquetamab (Talvey)		
					Ramantamig (JNJ-79635322)		
<b>Dara</b>	<b>Cy</b>	<b>Bor</b>	<b>D</b>				
Daratumumab (Darzalex)	Cyclophosphamide (Cytoxan)	Bortezomib (Velcade)	Dexamethasone (Decadron)				

**Bold Black:**  
FDA-Approved

Standard Black:  
Available Off Label

Standard Red:  
Investigational

\* Ciltacabtagene Autoleucl (CARVYKTI): BCMA  
 Idecabtagene Vicleucl (ABECMA) BCMA  
 NXC-201 (previously HBI0101) BCMA  
 AZD0120 (formerly known as GC012F) BCMA and CD19



CANCER INSTITUTE

Wayne State University